SCHEMBL473378

SCHEMBL473378

CCN(CC)C(C)Nc1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.52
TSHR P16473 4/20 0.45
ALDH1A1 P00352 4/20 0.45
CYP3A4 P08684 3/20 0.45
ALOX15 P16050 3/20 0.45
HSD17B10 Q99714 3/20 0.45
L3MBTL1 Q9Y468 3/20 0.45
ALOX12 P18054 2/20 0.45
THRB P10828 2/20 0.45
LMNA P02545 1/20 0.45
RECQL P46063 1/20 0.45
ATM Q13315 1/20 0.45
HIF1A Q16665 2/20 0.43
MAPK1 P28482 1/20 0.43
PGR P06401 1/20 0.43
ADRA2A P08913 1/20 0.43
ADRA2B P18089 1/20 0.43
HTR2A P28223 1/20 0.43
HRH1 P35367 1/20 0.43
KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL473354 0.98 TDP1 (0.50) TDP1TSHRALDH1A1CYP3A4ALOX15
SCHEMBL11307286 0.84 TDP1 (0.48) TDP1TSHRALDH1A1CYP3A4ALOX15
SCHEMBL8157670 0.78 TDP1 (0.45) TDP1TSHRALDH1A1CYP3A4ALOX15
SCHEMBL27666006 0.76 TDP1 (0.43) TDP1TSHRALDH1A1CYP3A4ALOX15
SCHEMBL11316811 0.76 TDP1 (0.58) TDP1TSHRALDH1A1CYP3A4ALOX15
SCHEMBL4457363 0.73 TDP1 (0.61) TDP1TSHRALDH1A1CYP3A4ALOX15
SCHEMBL28742618 0.72 KCNN4 (0.48) ALDH1A1HSD17B10PGRADRA2AADRA2B
SCHEMBL3123228 0.72 ADRA2A (0.34) ALDH1A1ALOX15HSD17B10ALOX12HIF1A
SCHEMBL7724502 0.72 KEAP1 (0.46) ALDH1A1L3MBTL1LMNAPGRADRA2A
SCHEMBL13776661 0.71 ALDH1A1 (0.77) TDP1TSHRALDH1A1CYP3A4ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1848719-B1 [1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THREONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES EXELIXIS INC (US) 2012-02-01 EP disclosed
US-7994172-B2 [1-(3-bromo-1H-pyrazolo[3,4-d]pyrimidin-4-yl)piperidin-4-yl](4-chlorophenyl)methanol; kinase-dependent diseases, invasive cell growth, and metabolism EXELIXIS, INC. (US) 2011-08-09 US disclosed
US-20080188482-A1 [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases EXELIXIS, INC. (US) 2008-08-07 US disclosed
EP-1848719-A1 [1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THREONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES Exelixis, Inc. (US) 2007-10-31 EP disclosed
WO-2006071819-A1 [1H-PYRAZOLO[3, 4-D]PYRIMIDIN-4-YL]-PIPERIDINE OR -PIPERAZINE COMPOUNDS AS SERINE-THEORONINE KINASE MODULATORS (P70S6K, ATK1 AND ATK2) FOR THE TREATMENT OF IMMUNOLOGICAL, INFLAMMATORY AND PROLIFERATIVE DISEASES EXELIXIS, INC. (US) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188482-A1 [1H-Pyrazolo[3, 4-D]Pyrimidin-4-Yl]-Piperidine or -Piperazine Compounds as Serine-Theoronine Kinase Modulators (P70s6k, Atk1 and Atk2) for the Treatment of Immunological, Inflammatory and Proliferative Diseases PDPK1, MTOR, RPS6KA2 TDP1 3909/4885TSHR 3177/4885ALDH1A1 4083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.